【摘要】 目的 探讨益心舒片辅助治疗心律失常的临床疗效。方法 将2020年7月至2021年7月该院收治的心律失常患者106例纳入研究，通过抽签法将入选患者随机分为观察组和对照组各53例。对照组患者给予常规西医治疗，观察组在对照组治疗方案的基础上采用益心舒片辅助治疗，比较两组患者的临床疗效、主要证候积分、心功能指标、血清生化指标及不良反应发生情况。结果 观察组总有效率为92.45%,对照组为75.47%,两组间比较差异有统计学意义(P<0.05)。治疗后，两组主要证候积分均较治疗前显著降低(P<0.05),两组间比较差异有统计学意义(P<0.05);两组左心室射血分数和6分钟步行距离均较治疗前增加(P<0.05),左心室收缩末期内径和左心室舒张末期内径均较治疗前减小(P<0.05),两组间上述4项指标比较差异均有统计学意义(P<0.05);两组核转录因子Kappa B、基质金属蛋白酶9和肿瘤坏死因子α水平均较治疗前显著降低(P<0.05),基质金属蛋白酶抑制因子-1水平较治疗前显著升高(P<0.05),两组间上述3项指标比较差异均有统计学意义(P<0.05)。治疗期间，观察组不良反应总发生率为5.66%,对照组为13.21%,两组比较差异无统计学意义(P>0.05)。结论 益心舒片辅助治疗心律失常疗效显著，可减轻患者临床症状、炎症反应和心肌受损情况，进而提高患者心功能，延缓病情进展，安全可靠，值得临床推广应用。更多还原

【Abstract】 Objective To investigate the clinical efficacy of Yixinshu tablet in the adjuvant treatment of arrhythmia.Methods A total of 106 patients with arrhythmia admitted to the hospital from July 2020 to July 2021 were enrolled in the study.The patients were randomly divided into the observation group and the control group, with 53 cases in each group.The control group was treated with conventional Western medicine, and the observation group was treated with Yixinshu tablets as an adjunct to the treatment regimen in the control group.The clinical efficacy, main syndrome scores, cardiac function indexes, serum biochemical indexes and adverse reactions were compared between the two groups.Results The total effective rate was 92.45% in the observation group and 75.47% in the control group, and the difference between the two groups was statistically significant(P<0.05).After treatment, the main syndrome scores of the two groups were significantly lower than those before treatment(P<0.05),and the difference between the two groups was statistically significant(P<0.05).The left ventricular ejection fraction and 6-minute walk distance in the two groups were higher than those before treatment(P<0.05),and the left ventricular end systolic diameter and left ventricular end diastolic diameter were lower than those before treatment(P<0.05).There were significant differences in the above four indicators between the two groups(P<0.05).The levels of nuclear factor Kappa B,matrix metalloproteinase 9(MMP-9) and tumor necrosis factor α in the two groups were significantly lower than those before treatment(P<0.05),and the level of matrix metalloproteinase inhibitor 1 was significantly higher than that before treatment(P<0.05).There were significant differences in the above three indicators between the two groups(P<0.05).During the treatment, the total incidence of adverse reactions was 5.66% in the observation group and 13.21% in the control group, and there was no statistically significant difference between the two groups(P>0.05).Conclusion Yixinshu tablet is effective in the adjuvant treatment of arrhythmia, can reduce the clinical symptoms, inflammatory response and myocardial damage, improve the cardiac function of patients, delay the progress of the disease, and is safe and reliable, which is worthy of clinical application.更多还原